Therapeutic cancer vaccines based on molecularly defined human tumor antigens

Vaccine

Volumn 20, Issue SUPPL. 4, 2002, Pages

  Romero, Pedro ^a   Pittet, Mikael ^a   Dutoit, Valerie ^a   Zippelius, Alfred ^a   Liénard, Danielle ^a   Lejeune, Ferdy ^a   Guillaume, Philippe ^b   Rimoldi, Donata ^b   Valmori, Danila ^a   Speiser, Daniel E ^a   Cerottini, Jean Charles ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Immunogenicity; Melanoma; T cells; Tetramers; Therapeutic cancer

Indexed keywords

BCR ABL BREAKPOINT PEPTIDE VACCINE; CANCER VACCINE; GLYCOPROTEIN GP 100; HER 2 VACCINE; HPV16 E7 VACCINE; INFLUENZA MATRIX VACCINE; MAGE 3 VACCINE; MELAN A; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; MUC 1 PEPTIDE VACCINE; PAN DR BINDING PEPTIDE VACCINE; PEPTIDE; PEPTIDE BASED VACCINE; TUMOR ANTIGEN; TYROSINASE PEPTIDE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER; CELL FUNCTION; CELL SPECIFICITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; DRUG SCREENING; EFFECTOR CELL; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; VACCINATION; ARTICLE; IMMUNOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0037137530     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00380-8     Document Type: Conference Paper

References (45)

1. Altman J.D., Moss P.A., Goulder P.J.et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274(5284):1996;94-96.
2. Gallimore A., Glithero A., Godkin A.et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 187(9):1998;1383-1393.
3. Pittet M.J., Zippelius A., Speiser D.E.et al. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J. Immunol. 166(12):2001;7634-7640.
4. Becker C., Pohla H., Frankenberger B.et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat. Med. 7(10):2001;1159-1162.
5. Lee P.P., Yee C., Savage P.A.et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5(6):1999;677-685.
6. Valmori D., Scheibenbogen C., Dutoit V.et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 62(6):2002;1743-1750.
7. Liu L., Chahroudi A., Silvestri G.et al. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat. Med. 8(2):2002;185-189.
8. Coulie P.G., Karanikas V., Colau D.et al. A monoclonal cytolytic T lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. U.S.A. 98(18):2001;10290-10295.
9. *0201-associated tyrosinase peptide. Cancer Res. 59(16):1999;4050-4055.
10. Valmori D., Dutoit V., Rubio-Godoy V.et al. Frequent cytolytic T cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res. 61(2):2001;509-512.
11. + T cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 60(16):2000;4499-4506.
12. Ayyoub M., Stevanovic S., Sahin U.et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 168(4):2002;1717-1722.
13. Zippelius A., Pittet M.J., Batard P.et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J. Exp. Med. 195(4):2002;485-494.
14. Pittet M.J., Valmori D., Dunbar P.R.et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190(5):1999;705-715.
15. Romero P., Dunbar P.R., Valmori D.et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188(9):1998;1641-1650.
16. Pittet M., Zippelius A., Valmori D., Speiser D., Cerottini J.C., Romero P. Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol. 23(7):2002;325-328.
17. Speiser D., Lienard D., Pittet M.et al. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen. Eur. J. Immunol. 32(3):2002;731-741.
18. Cormier J.N., Salgaller M.L., Prevette T.et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan-A. Cancer J. Sci. Am. 3(1):1997;37-44.
19. Rosenberg S.A., Yang J.C., Schwartzentruber D.J.et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4(3):1998;321-327.
20. + T cells after vaccination with antigenic peptide. Clin. Cancer Res. 7(3 Suppl.):2001;796s-803s.
21. Valmori D., Dutoit V., Schnuriger V.et al. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J. Immunol. 168:2002;4231-4240.
22. van der Bruggen P., Traversari C., Chomez P.et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254(5038):1991;1643-1647.
23. Moingeon P., Leclerc C. Challenges and issues in new vaccine development. Trends Immunol. 23(4):2002;173-175.
24. Haanen J.B., van Oijen M.G., Tirion F.et al. In situ detection of virus- and tumor-specific T cell immunity. Nat. Med. 6(9):2000;1056-1060.
25. Skinner P.J., Daniels M.A., Schmidt C.S., Jameson S.C., Haase A.T. Cutting edge: in situ tetramer staining of antigen-specific T cells in tissues. J. Immunol. 165(2):2000;613-617.
26. Andersen M.H., Pedersen L.O., Capeller B., Brocker E.B., Becker J.C., thor Straten P. Spontaneous cytotoxic T cell responses against survivin-derived MHC class I-restricted T cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 61(16):2001;5964-5968.
27. Dickinson A.M., Wang X.N., Sviland L. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat. Med. 8(4):2002;410-414.
28. Wang E, Miller LD, Ohnmacht GA, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002;62(13):3584-6.
29. Marincola F.M., Jaffee E.M., Hicklin D.J., Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:2000;181-273.
30. Rosenberg S.A. Progress in human tumor immunology and immunotherapy. Nature. 411(6835):2001;380-384.
31. Marchand M., van Baren N., Weynants P.et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer. 80(2):1999;219-230.
32. Jager E., Ringhoffer M., Dienes H.P.et al. Granulocyte-macrophage colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer. 67(1):1996;54-62.
33. Reddish M., MacLean G.D., Koganty R.R.et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int. J. Cancer. 76(6):1998;817-823.
34. Lee P., Wang F., Kuniyoshi J.et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19(18):2001;3836-3847.
35. van Driel W.J., Ressing M.E., Kenter G.G.et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phases I and II trial. Eur. J. Cancer. 35(6):1999;946-952.
36. Pinilla-Ibarz J., Cathcart K., Korontsvit T.et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 95(5):2000;1781-1787.
37. Scheibenbogen C., Schmittel A., Keilholz U.et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother. 23(2):2000;275-281.
38. Muderspach L., Wilczynski S., Roman L.et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 6(9):2000;3406-3416.
39. Knutson K.L., Schiffman K., Disis M.L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T cell immunity in cancer patients. J. Clin. Invest. 107(4):2001;477-484.
40. Nestle F.O., Alijagic S., Gilliet M.et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4(3):1998;328-332.
41. Thurner B., Haendle I., Roder C.et al. Vaccination with MAGE-3.A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190(11):1999;1669-1678.
42. Banchereau J., Palucka A.K., Dhodapkar M.et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61(17):2001;6451-6458.
43. Fong L., Hou Y., Rivas A.et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 98(15):2001;8809-8814.
44. Timmerman J.M., Czerwinski D.K., Davis T.A.et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 99(5):2002;1517-1526.
45. Schuler-Thurner B., Schultz E.S., Berger T.G.et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195(10):2002;1279-1288.